Open AccessImpact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
Author(s) -
Søren S. Lund,
Lise Tarnow,
Coen D.A. Stehouwer,
Casper G. Schalkwijk,
Tom Teerlink,
Jørgen Gram,
K. Winther,
M. Frandsen,
U. Smidt,
Oluf Pedersen,
HansHenrik Parving,
Allan Vaag
Publication year - 2008
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje-07-0815
Subject(s) - metformin , medicine , repaglinide , endocrinology , type 2 diabetes , diabetes mellitus , plasminogen activator , insulin resistance , endothelial dysfunction , von willebrand factor , type 2 diabetes mellitus , insulin , plasminogen activator inhibitor 1 , body mass index , platelet
In patients with type 2 diabetes mellitus (T2DM), biomarkers reflecting inflammation and endothelial dysfunction have been linked to cardiovascular disease (CVD biomarkers) and metabolic regulation. In T2DM patients, metformin and insulin secretagogues have demonstrated equal anti-hyperglycaemic potency. Here, we report the effect of metformin versus an insulin secretagogue, repaglinide, on CVD biomarkers in non-obese T2DM patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom